EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 (Novembre 2023) Hors série n° 1 Med Sci (Paris), 39 (2023) 6-10 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 39, Novembre 2023
Les Cahiers de Myologie
Page(s) 6 - 10
Section Mise au point
DOI https://doi.org/10.1051/medsci/2023130
Publié en ligne 17 novembre 2023
  1. SpiroAJ, ShyGM, GonatasNK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966 ; 14 : 1–14. [CrossRef] [PubMed] [Google Scholar]
  2. LaporteJ, HuLJ, KretzC, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996 ; 13 : 175–182. [CrossRef] [PubMed] [Google Scholar]
  3. Laporte J, Bedez F, Bolino A, et al. Myotubularins, a large disease-associated family of cooperating catalytically active and inactive phosphoinositides phosphatases. Hum Mol Genet 2003; 12 (spécial n° 2) : R285–92. [CrossRef] [PubMed] [Google Scholar]
  4. NicotAS, ToussaintA, ToschV, et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy. Nat Genet 2007 ; 39 : 1134–1139. [CrossRef] [PubMed] [Google Scholar]
  5. BohmJ, BiancalanaV, MalfattiE, et al. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain 2014 ; 137 : 3160–3170. [CrossRef] [PubMed] [Google Scholar]
  6. ToschV, RohdeHM, TronchereH, et al. A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Hum Mol Genet 2006 ; 15 : 3098–3106. [CrossRef] [PubMed] [Google Scholar]
  7. BevilacquaJA, MonnierN, BitounM, et al. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalisation and large areas of myofibrillar disorganisation. Neuropathol Appl Neurobiol 2011 ; 37 : 271–284. [CrossRef] [PubMed] [Google Scholar]
  8. JungbluthH, ZhouH, SewryCA, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2007 ; 17 : 338–345. [CrossRef] [PubMed] [Google Scholar]
  9. AgrawalPB, PiersonCR, JoshiM, et al. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet 2014 ; 95 : 218–226. [CrossRef] [PubMed] [Google Scholar]
  10. Ceyhan-BirsoyO, AgrawalPB, HidalgoC, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 2013 ; 81 : 1205–1214. [CrossRef] [PubMed] [Google Scholar]
  11. BohmJ, BiancalanaV, DecheneET, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012 ; 33 : 949–959. [CrossRef] [PubMed] [Google Scholar]
  12. BitounM, MaugenreS, JeannetPY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005 ; 37 : 1207–1209. [CrossRef] [PubMed] [Google Scholar]
  13. FischerD, HerasseM, BitounM, et al. Characterization of the muscle involvement in dynamin 2- related centronuclear myopathy. Brain 2006 ; 129 : 1463–1469. [CrossRef] [PubMed] [Google Scholar]
  14. HanischF, MullerT, DietzA, et al. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. J Neurol 2011 ; 258 : 1085–1090. [CrossRef] [PubMed] [Google Scholar]
  15. BitounM, BevilacquaJA, PrudhonB, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007 ; 62 : 666–670. [CrossRef] [PubMed] [Google Scholar]
  16. SusmanRD, Quijano-RoyS, YangN, et al. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscul Disord 2010 ; 20 : 229–237. [CrossRef] [PubMed] [Google Scholar]
  17. JungbluthH, CullupT, LillisS, et al. Centronuclear myopathy with cataracts due to a novel dynamin 2 (DNM2) mutation. Neuromuscul Disord 2010 ; 20 : 49–52. [CrossRef] [PubMed] [Google Scholar]
  18. MelbergA, KretzC, KalimoH, et al. Adult course in dynamin 2 dominant centronuclear myopathy with neonatal onset. Neuromuscul Disord 2010 ; 20 : 53–56. [CrossRef] [PubMed] [Google Scholar]
  19. BitounM, BevilacquaJA, EymardB, et al. A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation. Neurology 2009 ; 72 : 93–95. [CrossRef] [PubMed] [Google Scholar]
  20. Gómez-Oca R, Cowling BS, Laporte J. Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances. IJMS 2021; 22 : 11377. [CrossRef] [Google Scholar]
  21. DurieuxAC, PrudhonB, GuicheneyP, et al. Dynamin 2 and human diseases. J Mol Med 2010 ; 88 : 339–350. [CrossRef] [PubMed] [Google Scholar]
  22. ZuchnerS, NoureddineM, KennersonM, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005 ; 37 : 289–294. [CrossRef] [PubMed] [Google Scholar]
  23. SambuughinN, GoldfarbLG, SivtsevaTM, et al. Adult-onset autosomal dominant spastic paraplegia linked to a GTPase-effector domain mutation of dynamin 2. BMC Neurol 2015 ; 15 : 223. [CrossRef] [PubMed] [Google Scholar]
  24. KoutsopoulosOS, KretzC, WellerCM, et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. Eur J Hum Genet 2013 ; 21 : 637–642. [CrossRef] [PubMed] [Google Scholar]
  25. Echaniz-LagunaA, NicotAS, CarreS, et al. Subtle central and peripheral nervous system abnormalities in a family with centronuclear myopathy and a novel dynamin 2 gene mutation. Neuromuscul Disord 2007 ; 17 : 955–959. [CrossRef] [PubMed] [Google Scholar]
  26. KierdaszukB, BerdynskiM, KarolczakJ, et al. A novel mutation in the DNM2 gene impairs dynamin 2 localization in skeletal muscle of a patient with late onset centronuclear myopathy. Neuromuscul Disord 2013 ; 23 : 219–228. [CrossRef] [PubMed] [Google Scholar]
  27. CowlingBS, ChevremontT, ProkicI, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest 2014 ; 124 : 1350–1363. [CrossRef] [PubMed] [Google Scholar]
  28. CowlingBS, ToussaintA, AmoasiiL, et al. Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness. Am J Pathol 2011 ; 178 : 2224–2235. [CrossRef] [PubMed] [Google Scholar]
  29. WangL, BarylkoB, ByersC, et al. Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers. J Biol Chem 2010 ; 285 : 22753–22757. [CrossRef] [PubMed] [Google Scholar]
  30. KennistonJA, LemmonMA. Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. EMBO J 2010 ; 29 : 3054–3067. [CrossRef] [PubMed] [Google Scholar]
  31. JamesNG, DigmanMA, RossJA, et al. A mutation associated with centronuclear myopathy enhances the size and stability of dynamin 2 complexes in cells. Biochim Biophys Acta 2014 ; 1840 : 315–321. [CrossRef] [Google Scholar]
  32. FaelberK, GaoS, HeldM, et al. Oligomerization of dynamin superfamily proteins in health and disease. Prog Mol Biol Transl Sci 2013 ; 117 : 411–443. [CrossRef] [PubMed] [Google Scholar]
  33. DurieuxAC, VignaudA, PrudhonB, et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010 ; 19 : 4820–4836. [CrossRef] [PubMed] [Google Scholar]
  34. FraysseB, DesaphyJF, RollandJF, et al. Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone. Neurobiol Dis 2006 ; 21 : 372–380. [CrossRef] [PubMed] [Google Scholar]
  35. GibbsEM, ClarkeNF, RoseK, et al. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy. J Mol Med (Berl) 2013 ; 91 : 727–737. [CrossRef] [PubMed] [Google Scholar]
  36. BragatoC, GaudenziG, BlasevichF, et al. Zebrafish as a model to investigate Dynamin 2-related diseases. Sci Rep 2016 ; 6 : 20466. [CrossRef] [PubMed] [Google Scholar]
  37. KutchukianC, SzentesiP, AllardB, et al. Impaired excitation-contraction coupling in muscle fibres from the dynamin2(R465W) mouse model of centronuclear myopathy. J Physiol 2017 ; 595 : 7369–7382. [CrossRef] [PubMed] [Google Scholar]
  38. FongyA, FalconeS, LaineJ, et al. Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model. Sci Rep 2019 ; 9 : 1580. [CrossRef] [PubMed] [Google Scholar]
  39. F Almeida C, Bitoun M, Vainzof M. Satellite cells deficiency and defective regeneration in dynamin 2-related centronuclear myopathy. FASEB J 2021; 35 : e21346. [CrossRef] [PubMed] [Google Scholar]
  40. DurieuxAC, VassilopoulosS, LaineJ, et al. A centronuclear myopathy - dynamin 2 mutation impairs autophagy in mice. Traffic 2012 ; 13 : 869–879. [CrossRef] [PubMed] [Google Scholar]
  41. Puri C, Manni MM, Vicinanza M, et al. A DNM2 Centronuclear myopathy mutation reveals a link between recycling endosome scission and autophagy. Dev Cell 2020; 53 : 154–68.e6. [CrossRef] [PubMed] [Google Scholar]
  42. Gonzalez-JamettAM, Baez-MatusX, OlivaresMJ, et al. Dynamin-2 mutations linked to Centronuclear Myopathy impair actin-dependent trafficking in muscle cells. Sci Rep 2017 ; 7 : 4580. [CrossRef] [PubMed] [Google Scholar]
  43. FranckA, LaineJ, MoulayG, et al. Clathrin plaques and associated actin anchor intermediate filaments in skeletal muscle. Mol Biol Cell 2019 ; 30 : 579–590. [CrossRef] [PubMed] [Google Scholar]
  44. RomeroNB, BitounM. Centronuclear myopathies. Semin Pediatr Neurol 2011 ; 18 : 250–256. [CrossRef] [PubMed] [Google Scholar]
  45. Muñoz XM, Kretz C, Silva-Rojas R, et al. Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin. JCI Insight 2020; 5 : e137899. [CrossRef] [PubMed] [Google Scholar]
  46. ZanoteliE, VerganiN, CamposY, et al. Mitochondrial alterations in dynamin 2-related centronuclear myopathy. Arq Neuropsiquiatr 2009 ; 67 : 102–104. [CrossRef] [PubMed] [Google Scholar]
  47. BitounM, DurieuxAC, PrudhonB, et al. Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis. Hum Mutat 2009 ; 30 : 1419–1427. [CrossRef] [PubMed] [Google Scholar]
  48. ShevchukAI, NovakP, TaylorM, et al. An alternative mechanism of clathrin-coated pit closure revealed by ion conductance microscopy. J Cell Biol 2012 ; 197 : 499–508. [CrossRef] [PubMed] [Google Scholar]
  49. SidiropoulosPN, MieheM, BockT, et al. Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination. Brain 2012 ; 135 : 1395–1411. [CrossRef] [PubMed] [Google Scholar]
  50. LiuYW, LukiyanchukV, SchmidSL. Common membrane trafficking defects of disease-associated dynamin 2 mutations. Traffic 2011 ; 12 : 1620–1633. [CrossRef] [PubMed] [Google Scholar]
  51. TrochetD, PrudhonB, JolletA, et al. Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing. Mol Ther Nucleic Acids 2016 ; 5 : e362. [CrossRef] [PubMed] [Google Scholar]
  52. TrochetD, PrudhonB, BeuvinM, et al. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy. EMBO Mol Med 2018 ; 10 : 239–253. [CrossRef] [PubMed] [Google Scholar]
  53. Trochet D, Prudhon B, Mekzine L, et al. Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy. Mol Ther Nucleic Acids 2022; 27 : 1179–90. [CrossRef] [PubMed] [Google Scholar]
  54. RabaiA, ReisserL, Reina-San-MartinB, et al. Allele-Specific CRISPR/Cas9 Correction of a Heterozygous DNM2 Mutation rescues centronuclear myopathy cell phenotypes. Mol Ther Nucleic Acids 2019 ; 16 : 246–256. [CrossRef] [PubMed] [Google Scholar]
  55. BuonoS, RossJA, TasfaoutH, et al. Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy. Proc Natl Acad Sci USA 2018 ; 115 : 11066–11071. [CrossRef] [PubMed] [Google Scholar]
  56. Lionello VM, Kretz C, Edelweiss E, et al. BIN1 modulation in vivo rescues dynamin-related myopathy. Proc Natl Acad Sci USA 2022; 119 : e2109576119. [CrossRef] [PubMed] [Google Scholar]
  57. CowlingBS, ProkicI, TasfaoutH, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest 2017 ; 127 : 4477–4487. [CrossRef] [PubMed] [Google Scholar]
  58. TasfaoutH, BuonoS, GuoS, et al. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice. Nat Commun 2017 ; 8 : 15661. [CrossRef] [PubMed] [Google Scholar]
  59. TasfaoutH, LionelloV, KretzCM, et al. Single intramuscular injection of AAV-shRNA reduces DNM2 and prevents myotubular myopathy in mice. Mol Ther 2018 ; 26 : 1082–1092. [CrossRef] [PubMed] [Google Scholar]
  60. Silva-Rojas R, Nattarayan V, Jaque-Fernandez F, et al. Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes. Mol Ther 2022; 30 : 868–80. [CrossRef] [PubMed] [Google Scholar]
  61. Li Q, Lin J, Widrick JJ, et al. Dynamin-2 reduction rescues the skeletal myopathy of SPEG-deficient mouse model. JCI Insight 2022; 7 : e157336. [CrossRef] [PubMed] [Google Scholar]
  62. Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014; 6 : 220ra10. [CrossRef] [PubMed] [Google Scholar]
  63. Dudhal S, Mekzine L, Prudhon B, et al. Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations. Mol Ther Nucleic Acids 2022; 29 : 733–48. [CrossRef] [PubMed] [Google Scholar]
  64. CowlingBS, ProkicI, TasfaoutH, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest 2017 ; 127 : 4477–4487. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.